Meeting
2019 ASCO Annual Meeting
A randomized phase II trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM).
Authors
Mustafa Khasraw
Royal North Shore Hospital/ University of Sydney, St Leonards, Australia
Mustafa Khasraw , Kerrie Leanne McDonald , Mark Rosenthal , Zarnie Lwin , David M. Ashley , Helen Wheeler , Elizabeth Barnes , Matthew C. Foote , Eng-Siew Koh , Erik P. Sulman , Michael Back , Michael Buckland , Hao-Wen Sim , Lauren Fisher , Robyn Leonard , Merryn Hall , Sonia Yip , John Simes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
ACTRN12615000407594
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2011)
DOI
10.1200/JCO.2019.37.15_suppl.2011
Abstract #
2011
Poster Bd #
200
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU study).
First Author: Mustafa Khasraw
Poster
2019 ASCO Annual Meeting
Health-related quality of life (HRQL) in VERTU: A randomized phase II trial of veliparib (V), radiotherapy (RT), and temozolomide (TMZ) for newly diagnosed MGMT unmethylated (uMGMT) glioblastoma (GBM).
First Author: Hao-Wen Sim
Poster
2023 ASCO Annual Meeting
A randomised phase II multicentre study of ipilimumab with temozolomide vs temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: Ipi-Glio.
First Author: Paul James Mulholland
Poster
2022 ASCO Annual Meeting
Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to temozolomide, a phase II study (NCT03643549).
First Author: Dorota Goplen